CareDx Stock News

Acushnet Holdings, CareDx, Lululemon and Chewy highlighted as Zacks Bull and Bear of the Day

This stock has beaten the Zacks Consensus Estimate in each of the last four quarters but it has fallen to the lowest Zacks Rank.

Overview of Global Human Leukocyte Antigen (HLA) Typing for Transplant Market: Human Leukocyte Antigen (HLA) Typing for Transplant is a professional and wide-ranging report containing market parameters about the Healthcare industry. The report pinpoints on the leading Market competitors with explaining

This stock has beaten the Zacks Consensus Estimate in each of the last four quarters but it has fallen to the lowest Zacks Rank.

CareDx, Inc (NASDAQ:CDNA) CFO Ankur Dhingra purchased 5,000 shares of the companys stock in a transaction that occurred on Wednesday, November 24th. The shares were purchased at an average cost of $42.34 per share, with a total value of $211,700.00. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which []

It doesn't take a lot to own a piece of these rapidly growing healthcare businesses.

Equities research analysts expect that CareDx, Inc (NASDAQ:CDNA) will announce earnings per share of $0.02 for the current quarter, Zacks Investment Research reports. Three analysts have issued estimates for CareDxs earnings, with the highest EPS estimate coming in at $0.03 and the lowest estimate coming in at $0.01. CareDx reported earnings per share of $0.08 []

Shares of CareDx, Inc (NASDAQ:CDNA) have been assigned an average rating of Buy from the eight research firms that are currently covering the stock, MarketBeat Ratings reports. One research analyst has rated the stock with a sell recommendation, one has given a hold recommendation, four have given a buy recommendation and one has given a []

Cubist Systematic Strategies LLC reduced its holdings in shares of CareDx, Inc (NASDAQ:CDNA) by 90.6% in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 5,319 shares of the companys stock after selling 51,119 shares during the period. Cubist Systematic Strategies []

CareDx Inc (NASDAQ:CDNA)s traded shares stood at 1.17 million during the last session, with the companys beta value hitting 0.52. At the close of trading, the stocks price was $44.13, to imply an increase of 1.38% or $0.6 in intraday trading. The CDNA shares 52-week high remains $99.83, putting it -126.22% down since that peak CareDx Inc (NASDAQ: CDNA) Thursdays Performance: Up 1.63% From The Lows, Now What? Read More »

SOUTH SAN FRANCISCO, Calif., Nov. 19, 2021 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq: CDNA) -- The Transplant Company focused on the discovery, development, and commercialization of clinically differ

SOUTH SAN FRANCISCO, Calif., Nov. 19, 2021 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq: CDNA) -- The Transplant Company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers, today announced its inclusion on the Deloitte Technology Fast 500 , a ranking of the 500 fastest-growing technology, media, telecommunications, life sciences, fintech, and energy tech companies in North America. This marks the third consecutive year that CareDx has been included on the Deloitte Technology Fast 500.

(PR-inside.com) SAN FRANCISCO, CA / ACCESSWIRE / November 18, 2021 / Hagens Berman urges CareDx, Inc. (NASDAQ:CDNA) investors to with significant losses to submit your losses now. Visit: http://www.hbsslaw.com/investor-fraud/CDNA Contact An Attorney Now: [email protected] 844-916-0895 CareDx, Inc. (CDNA) Investigation: The investigation centers on the accuracy of CareDx''s statements concerning its business practices, accounting, and public reporting, particularly pertaining to the company''s kidney testing and phlebotomy services. On Oct. 28, 2021, after the market closed, CareDx released Q3 2021 financial results in which the company disclosed that the U.S. Department of Justice ("DOJ") had recently served a civil investigatory demand requesting documents in connection with a False Claims ..

CareDx (NASDAQ:CDNA) and Genetron (NASDAQ:GTH) are both medical companies, but which is the better investment? We will contrast the two companies based on the strength of their valuation, analyst recommendations, profitability, dividends, earnings, risk and institutional ownership. Risk & Volatility CareDx has a beta of 0.52, meaning that its stock price is 48% less volatile []

SAN FRANCISCO, Nov. 15, 2021 (GLOBE NEWSWIRE) -- Hagens Berman urges CareDx, Inc. (NASDAQ: CDNA) investors to with significant losses to submit your losses now .